Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities

This program provide an update of novel findings in basic and clinical science with regard to the association of triglyceride-rich remnant lipoproteins and CV risk. In addition, guidance will be given how to apply these findings in the treatment of patients in clinical practice.

Episodes 1-3 of 3

  • Targeting triglyceriderich remnant lipoproteinsTargeting triglyceriderich remnant lipoproteins
    Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities
    Targeting triglyceride-rich remnant lipoproteins
    • Prof. Daniel Gaudet, MD, PhD
      Prof. Daniel Gaudet, MD, PhD

      Prof. Daniel Gaudet, MD, PhD

  • Why focus on triglyceriderich lipoproteins and their remnantsWhy focus on triglyceriderich lipoproteins and their remnants
    Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities
    Why focus on triglyceride-rich lipoproteins and their remnants?
    • Prof. Henry Ginsberg, MD
      Prof. Henry Ginsberg, MD

      Prof. Henry Ginsberg, MD

  • Triglyceriderich lipoproteins and residual CV riskTriglyceriderich lipoproteins and residual CV risk
    Targeting TG-rich remnant lipoproteins: Review of new insights and clinical opportunities
    Triglyceride-rich lipoproteins and residual CV risk
    • Prof. Erik Stroes, MD
      Prof. Erik Stroes, MD

      Prof. Erik Stroes, MD

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free